NovoCure
NVCR
304 hedge funds and large institutions have $6.2B invested in NovoCure in 2022 Q4 according to their latest regulatory filings, with 49 funds opening new positions, 97 increasing their positions, 90 reducing their positions, and 40 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
23% more first-time investments, than exits
New positions opened: 49 | Existing positions closed: 40
1.06% more ownership
Funds ownership: 79.64% → 80.7% (+1.1%)
8% more repeat investments, than reductions
Existing positions increased: 97 | Existing positions reduced: 90
0% more funds holding
Funds holding: 303 → 304 (+1)
2% less capital invested
Capital invested by funds: $6.34B → $6.2B (-$131M)
30% less call options, than puts
Call options by funds: $137M | Put options by funds: $196M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$98.5M |
| 2 |
HIC
Hartline Investment Corp
Winnetka,
Illinois
|
+$22.9M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$22.3M |
| 4 |
BlackRock
New York
|
+$17M |
| 5 |
Aviva
London,
United Kingdom
|
+$9.09M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$98.3M |
| 2 |
Morgan Stanley
New York
|
-$33.3M |
| 3 |
State Street
Boston,
Massachusetts
|
-$29.1M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$15.3M |
| 5 |
Mitsubishi UFJ Trust & Banking
Tokyo,
Japan
|
-$12.3M |
NVCR Hedge Fund Activity: Q4 2022 in Review
304 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in NovoCure (NVCR) for Q4 2022, worth a combined $6.2B — down 2.1% from $6.34B a quarter earlier.
Buyers outnumbered sellers: 49 funds opened new NVCR positions and 40 closed out — a net gain of 9 holders — while 97 added to existing stakes and 90 trimmed.
The largest buyer was Vanguard Group, adding an estimated $98.5M. The largest seller was Deep Track Capital, exiting entirely with an estimated $98.3M sold.
- 304 institutional investors held NovoCure (NVCR) as of Q4 2022, up from 303 in Q3 2022.
- Funds reported $6.2B of NovoCure stock for Q4 2022, down 2.1% quarter-over-quarter.
- 49 funds opened new NovoCure positions in Q4 2022 and 40 closed out, a net change of +9 holders.
- The largest NovoCure buyer in Q4 2022 was Vanguard Group, an estimated $98.5M added.
- The largest NovoCure seller in Q4 2022 was Deep Track Capital, an estimated $98.3M sold.
Based on aggregated 13F filings for Q4 2022.